Skip to Main Content

SAN FRANCISCO — Amarin (AMRN) CEO John Thero used his Wednesday breakout session at the J.P. Morgan Healthcare Conference to not-so-subtly telegraph a stronger 2019 sales outlook for Vascepa than the company’s official guidance offered last week.

Thero, of course, can’t come out directly and say that Vascepa, Amarin’s heart drug derived from fish oil, will deliver significantly more than a 50 percent year-over-year increase to $350 million in 2019 sales. Like Fight Club, the first rule of sandbagging revenue guidance is not talking about sandbagging revenue guidance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Anyone that has been following this stock knew the company was under reporting guidance…And once they get FDA approval by year end for multi purpose labeling there will be takeover or partnership offers from big pharma….

Comments are closed.